Details of the Drug Combinations

General Information of This Drug (ID: DMW1TV2)

Drug Name
Rifaximin   DMW1TV2
Synonyms RCIFAX; Rifaximin (bioadhesive/ gastrointestinal extended release); Rifaximin (bioadhesive/ gastrointestinal extended release), Salix Pharmaceuticals
Indication
Disease Entry ICD 11 Status REF
Bacterial infection 1A00-1C4Z Approved [1]
Diarrhea-predominant irritable bowel syndrome DD91.01 Approved [2]
Hepatic encephalopathy DB99.5 Approved [2]
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
Rifaximin + Marizomib DCNCNFT Marizomib Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [3]
------------------------------------------------------------------------------------
10 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Framycetin + Rifaximin DCSZYVH Framycetin Constipation-predominant Irritable Bowel Syndrome [4]
Lactulose + Rifaximin DCDAGVV Lactulose Hepatic Encephalopathy [5]
Rifaximin + Acetylcysteine DCGWCSC Acetylcysteine Irritable Bowel Syndrome With Diarrhea [6]
Ciprofloxacin XR + Rifaximin DCRVLWR Ciprofloxacin XR Crohn Disease [7]
Simvastatin + Rifaximin DC47PP4 Simvastatin Cirrhoses, Liver [8]
Simvastatin + Rifaximin DCNO4DX Simvastatin Liver Cirrhoses [9]
Azathioprine + Rifaximin DCUJT92 Azathioprine Crohn Disease [10]
Lactulose + Rifaximin DC6D8L5 Lactulose Hepatic Encephalopathy [11]
Loperamide + Rifaximin DC0NCNQ Loperamide Diarrhoea;Acute [12]
Mebeverine + Rifaximin DCUBFKK Mebeverine Irritable Bowel Syndrome With Diarrhea [13]
------------------------------------------------------------------------------------
⏷ Show the Full List of 10 DrugCom(s)

References

1 ClinicalTrials.gov (NCT01654939) Impact of an Antibiotic (Rifaximin) on Liver Scarring in HIV-Infected Patients With Liver Disease. U.S. National Institutes of Health.
2 Rifaximin FDA Label
3 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
4 ClinicalTrials.gov (NCT00945334) Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation Predominant Irritable Bowel Syndrome
5 ClinicalTrials.gov (NCT00364689) RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial
6 ClinicalTrials.gov (NCT04557215) Efficacy and Safety of Rifaximin With NAC in IBS-D
7 ClinicalTrials.gov (NCT02620007) Evaluation of Adherent Invasive E. Coli Eradication in Adult Crohn Disease
8 ClinicalTrials.gov (NCT03150459) Simvastatin Plus Rifaximin in Decompensated Cirrhosis
9 ClinicalTrials.gov (NCT03780673) Efficacy of the Combination of Simvastatin Plus Rifaximin in Patients With Decompensated Cirrhosis to Prevent ACLF Development
10 ClinicalTrials.gov (NCT03185611) Effectiveness of Rifaximin Combined With Thiopurine on Preventing Postoperative Recurrence in Crohn's Disease
11 ClinicalTrials.gov (NCT01842581) The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy
12 ClinicalTrials.gov (NCT05677282) Single Dose Antibiotic Treatment of Acute Watery Diarrhea, Rifaximin Versus Azithromycin, With Loperamide Adjunct
13 ClinicalTrials.gov (NCT05867550) To Compare the Efficacy of Drugs in Combination for Treating Irritable Bowel Syndrome Associated With Diarrhea